Biotech Values

[iwfal]

SNTA -

CFO answered a question on the call basically by saying "if we have a phase 3 ready unencumbered oncology asset, we'll have plenty of options"

I'd suggest this is naive - after watching many of these deals I suspect that companies without, say, 12 months of cash on hand get substantially poorer deals than companies with >=24 months of cash.

Anyone know of any company that had less than 12 months of cash on hand that got a good deal for a ph ii compound - (e.g. >15% royalties plus partner covers all trial costs)?